Marine fungus-derived benzoquinone derivative embelin A as well as preparation method and application thereof

Embelin A, prepared by isolating from the marine fungus Penicillium sp. SCSIO 41411, solves the long-term adverse reaction problem of existing prostate cancer treatments, and provides a safe and effective anti-prostate cancer drug with a significant inhibitory effect on the proliferation of prostate cancer cells.

CN118993869APending Publication Date: 2024-11-22SOUTH CHINA SEA INST OF OCEANOLOGY CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411089748.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing treatments for prostate cancer have long-term adverse effects, and there is an urgent need to find safe and effective anti-prostate cancer drugs.

Method used

Embelin A, a benzoquinone derivative, was isolated and prepared from the fermentation product of the marine fungus Penicillium sp. SCSIO 41411. The compound embryolin A was purified by ethyl acetate extraction, rotary evaporation, silica gel column chromatography, and semi-preparative HPLC for use in the preparation of an anti-prostate cancer drug.

Benefits of technology

Embelin A significantly inhibits the proliferation of prostate cancer cells and has good anti-prostate cancer cell activity, providing a new drug option for the treatment of prostate cancer and showing important clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118993869A_ABST
    Figure CN118993869A_ABST
Patent Text Reader

Abstract

The invention discloses a benzoquinone derivative embelin A derived from marine fungi as well as a preparation method and application of the benzoquinone derivative embelin A. The structural formula of the compound embelin A is as shown in formula (I). The compound embelin A is prepared and separated from a fermentation product of the marine fungus Penicillium sp.SCSIO 41411, and the compound embelin A is prepared and separated from the fermentation product of the marine fungus Penicillium sp.SCSIO 41411. The embelin A has a good effect of inhibiting prostatic cancer PC-3 cell proliferation, IC50 is 18.69 + / -1.75 mu M, and the embelin A can be used for preparing the anti-prostatic cancer medicine. Therefore, the invention provides an alternative compound for developing new anti-prostatic cancer drugs, and has important significance for developing Chinese marine drug resources. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural product application, and specifically relates to a benzoquinone derivative embelin A derived from marine fungi, and a preparation method and application thereof. Background Art

[0002] Prostate cancer (PCa) is one of the most common malignant tumors in men. The incidence of prostate cancer in Chinese men has been on the rise from 2000 to 2018. The pathogenesis of prostate cancer may be related to genetic factors, age, and exogenous factors such as alcohol intake. There are no obvious symptoms in the early stages of prostate cancer. When the tumor grows to the point of compressing nearby organs and tissues, the symptoms are the same as those of benign prostatic hyperplasia, mainly manifested as urinary tract symptoms such as frequent urination, urgency, and difficulty urinating. Advanced prostate cancer will metastasize to distant organs.

[0003] Currently, the main treatments for this disease include radical prostatectomy, external radiation therapy, brachytherapy, proton therapy, endocrine therapy, and chemotherapy. However, long-term endocrine therapy and chemotherapy can cause a variety of adverse reactions, such as increased risk of acute kidney injury and cardiovascular disease. Therefore, it is urgent to find a new safe and effective anti-prostate cancer drug to meet the clinical demand for anti-prostate cancer. Summary of the invention

[0004] The first object of the present invention is to provide a benzoquinone derivative embelin A or a pharmaceutically acceptable salt thereof having a novel structure for inhibiting the activity of prostate cancer cells, the chemical structure of which is shown in formula (I):

[0005]

[0006] The second object of the present invention is to provide a method for preparing the above compound embelin A, which is prepared by separating and preparing the compound from the fermentation product of the marine fungus Penicillium sp. SCSIO 41411. The method specifically comprises the following steps:

[0007] (a) preparing a fermentation product of Penicillium sp.SCSIO 41411;

[0008] (b) The fermentation product obtained in step (a) is extracted with ethyl acetate, and concentrated by rotary evaporation to obtain an extract, which is subjected to normal phase silica gel column chromatography using a gradient elution of petroleum ether / dichloromethane at a volume ratio of 0-100% and dichloromethane / methanol at a volume ratio of 0-100%, and fractions Frs.1-15 are obtained after TLC spot plate analysis. Fraction Fr.2 is purified by semi-preparative HPLC using a COSMOSILπNAP column and isocratic elution of 72% CH3OH / H2O to separate and obtain compound embelin A.

[0009] Preferably, the fermentation product in step (a) is prepared by the following method: the fungus Penicillium sp. SCSIO 41411 is inoculated into a seed culture medium, and the seed liquid is obtained by shaking culture, and the seed liquid is inoculated into a sterilized rice culture medium for fermentation to obtain a fermentation product.

[0010] Preferably, the seed culture medium contains 15 g malt extract and 20 g sea salt per liter, and the solvent is water.

[0011] Preferably, the rice culture medium is obtained by mixing 230 mL of H2O and 8.8 g of sea salt per 200 g of rice.

[0012] The third object of the present invention is to provide the use of the compound embelin A or a pharmaceutically acceptable salt thereof in the preparation of an anti-prostate cancer drug.

[0013] The fourth object of the present invention is to provide an anti-prostate cancer drug, which comprises an effective amount of the compound embelin A or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.

[0014] Preferably, the content of the compound embelin A or its pharmaceutically acceptable salt in the drug is 1-99% by mass.

[0015] The fifth object of the present invention is to provide the use of the marine fungus Penicillium sp.SCSIO 41411 in the preparation of the compound embelin A or its pharmaceutically acceptable salt, wherein the deposit number of the Penicillium sp.SCSIO 41411 is GDMCC No: 62687.

[0016] The benzoquinone derivative embelin A of the present invention has a significant effect of inhibiting the proliferation of prostate cancer cells and can be used to prepare anti-prostate cancer drugs. Therefore, the present invention provides an alternative compound for the development of new anti-prostate cancer drugs and has important significance for the development of China's marine drug resources.

[0017] The fungus Penicillium sp.SCSIO 41411 was deposited on August 4, 2022 in the Guangdong Microbiological Culture Collection Center (GDMCC), address: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences, Postal Code: 510070, and its deposit number is GDMCC No: 62687. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The chemical structure of embelin A, a benzoquinone derivative.

[0019] Figure 2 for embelin A 1 H- 1 H COSY and HMBC key 2D NMR related information diagram.

[0020] Figure 3 This is the configuration diagram of embelin A shown by X-ray single crystal diffraction. DETAILED DESCRIPTION

[0021] In order to make the purpose, technical scheme and beneficial technical effect of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. It should be understood that the embodiments described in this specification are only for explaining the present invention, not for limiting the present invention.

[0022] Example 1 Fermentation of Penicillium sp. SCSIO 41411 and Isolation of embelin A

[0023] (1) Strain isolation and preservation: Penicillium sp. SCSIO 41411 was isolated from the rhizosphere mud of Aegiceras corniculatum collected from Gaoqiao Mangrove Nature Reserve and preserved in the Key Laboratory of Tropical Marine Bioresources and Ecology, Chinese Academy of Sciences (Guangzhou).

[0024] (2) Fermentation: The components of the seed culture medium (15 g malt extract, 20 g sea salt) were dissolved in 1 L distilled water and divided into 500 mL triangular flasks (200 mL / bottle, 5 bottles). 10-15 glass beads were added to each bottle to prevent the mycelium from shaking into a mass. After the bottle was sealed with cotton plugs and wrapped, it was sterilized in an autoclave at 121°C for 180 min. After the sterilized culture medium was cooled, the mycelium of the fungus Penicillium sp.SCSIO 41411 was picked from the agar plate and inoculated into the bottle, and the bottle was shaken on a shaker at 28°C (180 rpm). After the seed fermentation liquid was cultured for 3 days, 20 mL of the seed fermentation liquid was taken and fermented in large quantities in each bottle of rice culture medium (200 g rice, 8.8 g sea salt, 230 mL H2O). The rice culture medium was prepared in 1 L triangular flasks and sterilized by autoclave, for a total of 80 bottles. The fermentation was carried out at a temperature of 26°C for 28 days to obtain the fermentation product.

[0025] (3) Extraction: After the fermentation of the rice culture medium is completed, it is soaked with an equal volume of ethyl acetate, then crushed, ultrasonicated for 15 min, and extracted with ethyl acetate three times until colorless. The extract is concentrated by rotary evaporation to obtain an extract concentrate (150.0 g).

[0026] (4) Separation: The extract was subjected to normal phase silica gel column chromatography, using petroleum ether / dichloromethane (0-100%, v / v) and dichloromethane / methanol (0-100%, v / v) for gradient elution, and 15 fractions (Frs.1-15) were obtained after TLC spot plate analysis. Fraction Fr.2 (petroleum ether / dichloromethane 50%, v / v) was purified by semi-preparative HPLC using a COSMOSILπNAP column (10×250 mm) and 72% CH3OH / H2O isocratic elution (3 mL / min), and the pure compound embelin A (2.4 mg) was isolated at a retention time of 18.2 min.

[0027] Example 2 Structural Identification of Embelin A

[0028] The chemical structure of the benzoquinone derivative embelin A isolated and obtained in Example 1 is shown in formula (I). The structure derivation process is as follows:

[0029]

[0030] Embelin A is a yellow solid. Its molecular formula is given by the molecular ion peak m / z 253.1442 ([M+H] + 253.1434) is determined as C 14 H 20 O4. Analysis of its 1D NMR (Table 1) and HSQC spectra showed two carbonyl carbon atom signals (δ C184.5,183.6), three olefin carbon signals (δ C 161.9,156.1,120.1), an olefinic methylene carbon signal (δ H / C 5.88 / 104.0), six methylene carbon signals (δ H / C 1.29 / 33.0, 1.29 / 30.6, 1.32 / 30.2, 1.43 / 29.2, 1.32 / 23.7, 2.40 / 23.3) and two methyl carbon signals (δ H / C 3.83 / 57.2, 0.90 / 14.4) (one of which is an oxygen methyl group). The above data indicate that embelin A has a quinone skeleton and a fatty acid chain. COSY correlations of H2-9 / H2-8 / H2-7 and H2-12 / H3-13 ( Figure 2 ) and the HMBC correlation of H3-13 / CH2-11 ( Figure 2 ) showed that C-7-C-13 was a fatty acid chain. The HMBC correlations of H2-7 / C-1, C-5, C-6 and H2-8 / C-6 showed that CH2-7 was located at C-6. The HMBC correlation of H3-14 / C-2 showed that 14-OCH3 was located at C-2. In addition, embelin A (CCDC 2363995, Figure 3 ) further confirmed the above planar structure interpretation. Embelin A has been previously identified as a synthetic product, which was synthesized to elucidate the structure-activity relationship of embelin derivatives in inhibiting α-glucosidase. Therefore, the compound was identified as embelin A. Here, we report for the first time that the compound was isolated from nature as a new natural product.

[0031] Table 1. Embelin A 1 H NMR and 13 C NMR data (700 and 175 MHz, deuterated methanol)

[0032]

[0033]

[0034] Example 3: Test of Embelin A's Anti-prostate Cancer Cell Activity

[0035] (1) Cell culture: Prostate cancer 22Rv1 and PC-3 cells were purchased from the Cell Bank of the Chinese Academy of Sciences. The cells were cultured in a 37°C, 5% CO2 incubator using a culture medium containing 10% (v / v) fetal bovine serum. Before subculturing, the cells were carefully observed under an inverted microscope until the cell adherence density reached about 80%. The cells were collected for subculturing or plated for experiments.

[0036] (2) Effect of compounds on prostate cancer cell activity: Prostate cancer cells in the logarithmic growth phase were selected and digested with trypsin. The cell concentration was adjusted to 5.0×10 4 After the cells were completely attached to the wall, the test compound was added (3 replicates), and the blank control group was added with complete culture medium containing 1% DMSO. After the compound was exposed for 72 hours, MTT reagent was added and the OD value at 570nm was detected.

[0037] (3) The inhibitory activity of embelin A on the proliferation of two prostate cancer cell lines, 22Rv1 and PC-3, was screened. The results showed that the new natural product embelin A showed stable moderate cytotoxicity against the prostate cancer cell line PC-3, with a cell survival rate of 65%. Further studies on the anti-prostate cancer cell effect of embelin A revealed that it had a good inhibitory effect on the proliferation of PC-3 cells, IC 50 was 18.69±1.75μM, which was significantly lower than that of the other two prostate cancer cell lines LNCaP (IC 50 31.62±1.12μM) and DU145 (IC 50 >100μM), its anti-PC-3 activity was the strongest. Among these three cell types, PC-3 is androgen-independent and has a moderate metastatic potential, so it is speculated that embelin A compounds inhibit the intermediate stage of prostate tumor development.

[0038] In summary, embelin A can inhibit the survival of prostate cancer cells, thereby inhibiting the development of prostate tumors. This suggests that embelin A has a potential therapeutic effect on prostate cancer and has a good clinical application prospect. The present invention is of great significance to the development of new drugs with independent intellectual property rights in China.

[0039] The above description is a detailed description of the preferred embodiments of the present invention, but the embodiments are not intended to limit the scope of the patent application of the present invention. All equivalent changes or modifications completed under the technical concept suggested by the present invention should fall within the scope of the patent covered by the present invention.

Claims

1. The compound embelin A or a pharmaceutically acceptable salt thereof, the chemical structure of which is shown in formula (I):

2. A method for preparing the compound embelin A according to claim 1, It is characterized in that The invention is separated and prepared from the fermentation product of the marine fungus Penicillium sp.SCSIO 41411. The deposit number of the Penicillium sp.SCSIO41411 is GDMCC No: 62687.

3. The preparation method according to claim 2, It is characterized in that The specific steps include: (a) preparing a fermentation product of Penicillium sp.SCSIO 41411; (b) extracting the fermented product obtained in step (a) with ethyl acetate, and concentrating it by rotary evaporation to obtain an extract, and the extract was subjected to normal phase silica gel column chromatography, using petroleum ether / dichloromethane at a volume ratio of 0-100% and dichloromethane / methanol at a volume ratio of 0-100% for gradient elution, and combining to obtain fractions Frs.1-15 based on TLC spot plate analysis, and fraction Fr.2 was purified by semi-preparative HPLC using a COSMOSILπNAP column using 72% CH 3 OH / H 2 O isocratic elution was performed to separate the compound embelin A.

4. The preparation method according to claim 3, It is characterized in that The fermentation product in step (a) is prepared by the following method: the fungus Penicillium sp.SCSIO 41411 is inoculated into a seed culture medium, and the seed liquid is obtained by shaking culture, and the seed liquid is inoculated into a sterilized rice culture medium for fermentation to obtain a fermentation product.

5. The preparation method according to claim 3, It is characterized in that The seed culture medium contains 15g of malt extract and 20g of sea salt per liter, and the solvent is water.

6. The preparation method according to claim 3, It is characterized in that The rice culture medium is 200g rice and 230mL H 2 O and 8.8g of sea salt.

7. Use of the compound embelin A or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of an anti-prostate cancer drug.

8. A drug for treating prostate cancer, It is characterized in that The invention comprises an effective amount of embelin A or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.

9. The drug according to claim 8, It is characterized in that The content of the compound embelin A or its pharmaceutically acceptable salt in the medicine is 1-99% by mass.

10. Use of the marine fungus Penicillium sp. SCSIO 41411 in the preparation of the compound embelin A or its pharmaceutically acceptable salt, wherein the deposit number of the Penicillium sp. SCSIO 41411 is GDMCC No: 62687.